Brainstorm Cell (BCLI)

$0.84 -0.33 (-28.21%)
Market Cap 11.51M
Revenue (ttm) 0.00
Net Income (ttm) -11.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 819,600
Avg Vol 1,676,626
Day's Range N/A - N/A
Shares Out 9.84M
Stochastic %K 34%
Beta 0.22
Analysts Strong Sell
Price Target $7.50

Company Profile

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 488 0460
Address:
1325 Avenue of Americas, 28th Floor, New York, United States
Cellsci
Cellsci May. 13 at 1:36 PM
$BCLI The exosome platform ? Man your really pushing it now, platform lol
0 · Reply
Cellsci
Cellsci May. 13 at 12:32 PM
$BCLI I think you mean promote him not hire him
0 · Reply
1968gibsongirl
1968gibsongirl May. 12 at 7:22 PM
$BCLI corporate update details? Time? Number?
0 · Reply
ALSCellTherapy
ALSCellTherapy May. 12 at 5:52 PM
$BCLI Makary out... https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014
0 · Reply
Condo3e
Condo3e May. 12 at 11:31 AM
$BCLI THE STRATEGIC TRUTH The exosome platform is worth far more outside BrainStorm than inside it. A spin‑out (Path A) or platform license (Path B) unlocks 10× more value than internal development. BrainStorm’s ALS baggage suppresses the exosome platform’s valuation. Separating it instantly re‑rates the asset.
0 · Reply
Condo3e
Condo3e May. 12 at 11:26 AM
$BCLI Implication: Strong, long‑dated IP around what the exosomes are, how they’re made, and what indications they target. In IP terms, BrainStorm is top‑quartile among exosome players, especially in neuro.
1 · Reply
mfglola
mfglola May. 10 at 8:22 PM
$BCLI From WSJ editorial, "Instead, Dr. Makary looked on as Dr. Prasad drove out scientists who didn't share his mission of restricting access to drugs whose benefits he didn't think justified their costs." Cost is not supposed to be part of FDA's mission but may be a reason for the slow walk of the CP. Approved cell therapies are often a one time treatment unlike nurown....
2 · Reply
uieriwer
uieriwer May. 10 at 10:30 AM
$BCLI Investors, patients amd everyone deserves better than this.
1 · Reply
Condo3e
Condo3e May. 9 at 11:36 PM
$BCLI Folks, QNC, Quantum E Motion is a stock to investigate
0 · Reply
DoctorJT
DoctorJT May. 9 at 5:01 AM
$BCLI based upon Clene’s invitation from the FDA this week to file an AA NDA based upon their P2 Nfl data, anyone here think Coya goes the same route and gets invited to apply as well this year? For pALS I hope so, as Tregs appear to be the real deal in halting ALS progression. Coya has a real biotech CEO at the helm. Crazy that some of these companies may get approval on P2 data alone and Chaim couldn’t get it over the line with a P2 and P3 and is having to do yet another P3. Good ol’ Chaim.
2 · Reply
Latest News on BCLI
No data available.
Cellsci
Cellsci May. 13 at 1:36 PM
$BCLI The exosome platform ? Man your really pushing it now, platform lol
0 · Reply
Cellsci
Cellsci May. 13 at 12:32 PM
$BCLI I think you mean promote him not hire him
0 · Reply
1968gibsongirl
1968gibsongirl May. 12 at 7:22 PM
$BCLI corporate update details? Time? Number?
0 · Reply
ALSCellTherapy
ALSCellTherapy May. 12 at 5:52 PM
$BCLI Makary out... https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014
0 · Reply
Condo3e
Condo3e May. 12 at 11:31 AM
$BCLI THE STRATEGIC TRUTH The exosome platform is worth far more outside BrainStorm than inside it. A spin‑out (Path A) or platform license (Path B) unlocks 10× more value than internal development. BrainStorm’s ALS baggage suppresses the exosome platform’s valuation. Separating it instantly re‑rates the asset.
0 · Reply
Condo3e
Condo3e May. 12 at 11:26 AM
$BCLI Implication: Strong, long‑dated IP around what the exosomes are, how they’re made, and what indications they target. In IP terms, BrainStorm is top‑quartile among exosome players, especially in neuro.
1 · Reply
mfglola
mfglola May. 10 at 8:22 PM
$BCLI From WSJ editorial, "Instead, Dr. Makary looked on as Dr. Prasad drove out scientists who didn't share his mission of restricting access to drugs whose benefits he didn't think justified their costs." Cost is not supposed to be part of FDA's mission but may be a reason for the slow walk of the CP. Approved cell therapies are often a one time treatment unlike nurown....
2 · Reply
uieriwer
uieriwer May. 10 at 10:30 AM
$BCLI Investors, patients amd everyone deserves better than this.
1 · Reply
Condo3e
Condo3e May. 9 at 11:36 PM
$BCLI Folks, QNC, Quantum E Motion is a stock to investigate
0 · Reply
DoctorJT
DoctorJT May. 9 at 5:01 AM
$BCLI based upon Clene’s invitation from the FDA this week to file an AA NDA based upon their P2 Nfl data, anyone here think Coya goes the same route and gets invited to apply as well this year? For pALS I hope so, as Tregs appear to be the real deal in halting ALS progression. Coya has a real biotech CEO at the helm. Crazy that some of these companies may get approval on P2 data alone and Chaim couldn’t get it over the line with a P2 and P3 and is having to do yet another P3. Good ol’ Chaim.
2 · Reply
Condo3e
Condo3e May. 8 at 6:34 PM
$BCLI Bloomberg @business · President Donald Trump plans to fire Food and Drug Administration Commissioner Marty Makary, following months of chaos at one of the country’s most important health agencies, according to a person familiar with the matter.
0 · Reply
Condo3e
Condo3e May. 8 at 3:36 PM
$BCLI Apparently the year of Chaim is a second half of the year event
2 · Reply
Pipemajors82
Pipemajors82 May. 8 at 1:33 AM
$BCLI https://www.facebook.com/share/r/16fXGrrnSq/
0 · Reply
bizness1957
bizness1957 May. 7 at 10:54 PM
$BCLI $CLNN The drugs are patented
1 · Reply
bizness1957
bizness1957 May. 7 at 10:25 PM
$BCLI $CLNN Well some firm just bought a million shares at $7 .
1 · Reply
ALSCellTherapy
ALSCellTherapy May. 7 at 8:08 PM
$BCLI $CLNN I get it you're all in and you really believe in your gold crystals.
2 · Reply
ALSCellTherapy
ALSCellTherapy May. 7 at 8:03 PM
$BCLI $CLNN Haha you guys are all quite defensive. I just posted an article. If so confident why so defensive?
2 · Reply
ALSCellTherapy
ALSCellTherapy May. 7 at 7:48 PM
$BCLI $CLNN I think this is the best part of the article... Allow me to translate: The Clene “drug” is gold microdust suspended in water.
1 · Reply
kcresskill12345
kcresskill12345 May. 7 at 7:42 PM
$BCLI $CLNN You're just spinning the usual biotech hit‑job: pretend the trials were total failures, ignore every survival/NfL signal, and paint any follow‑up analysis as desperation. It’s the classic short‑seller move — leave out half the story and hope people don’t know the FDA already validated the biomarker path. Just stick to your favorite penny stock $BCLI that has lost 99% of its value and on the verge of bankrupt. Try harder, then I may consider selling a half of my position just for you.
2 · Reply
ALSCellTherapy
ALSCellTherapy May. 7 at 7:34 PM
$BCLI $CLNN Part 4 “May” is doing extraordinary work in that sentence, likely a lot more than the 2%-3% reduction in neurofilament attributed to CNM-Au8. The announcement boosted Clene shares by 40%, after which the company sold stock and raised $7 million. That’s worth a lot more than all the gold in CNM-Au8.
3 · Reply
ALSCellTherapy
ALSCellTherapy May. 7 at 7:32 PM
$BCLI $CLNN Part 3 In 2023, the FDA granted accelerated approval to a Biogen drug, called Qalsody, for a rare genetic type of ALS based on a 55% reduction in plasma neurofilament. The FDA concluded that significant and meaningful reductions in neurofilament were reasonably likely to predict clinical benefit for patients. In its clinical trials, Clene’s CNM-Au8 reduced plasma neurofilament by 2%-3%, depending on the time period measured, according to the company. On Monday, Clene announced a plan to submit a marketing application for CNM-Au8 to the FDA in the third quarter. In a press release, Clene said it had a “successful” meeting with the FDA, at which regulators told the company that its “proposed data may be capable of supporting the submission and review” of a marketing application seeking accelerated approval of CNM-Au8 for the treatment of ALS, Clene said.
0 · Reply
ALSCellTherapy
ALSCellTherapy May. 7 at 7:29 PM
$BCLI $CLNN Part 2 CNM-Au8 was investigated in two randomized, placebo-controlled clinical trials. Neither of the studies was successful. Clene’s drug failed to slow disease progression or prolong the survival of ALS patients compared to a placebo. The studies were completed in 2021 and 2022. For the last five years, Clene has retrospectively mined the data, trying to conjure rationalizations to explain away the ineffectiveness of CNM-Au8, while simultaneously positing various unproven hypotheses to justify the drug’s continued development and potential approval as a new treatment for ALS. This is standard C-list biotech behavior. When the studies fail, torture the dataset until it reveals something that might appear positive. Currently, Clene is pursuing an effort to secure accelerated approval from the FDA for CNM-Au8, based on a purported reduction in levels of neurofilament, a protein in plasma that is toxic to nerves. The approach is grounded in scientific truth.
0 · Reply